Semaglutide for Insulin Resistance
GLP-1 medications directly improve insulin sensitivity. Semaglutide (Wegovy/Ozempic) is a GLP-1 receptor agonist shown to produce 15% average body weight loss in clinical trials.
How Semaglutide Helps with Insulin Resistance
Semaglutide mimics the GLP-1 hormone to reduce appetite and slow stomach emptying, leading to significant weight loss. For patients with insulin resistance, this weight loss translates to meaningful improvements in condition-specific outcomes.
GLP-1 medications directly improve insulin sensitivity. The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly produces an average weight loss of 15% of body weight over 68 weeks, with additional benefits for metabolic health markers.
Clinical Evidence for Insulin Resistance
Insulin Resistance affects Up to 40% of adults. Research shows that GLP-1 medications like semaglutide address both the weight component and the underlying metabolic dysfunction associated with insulin resistance. Patients with this condition often see compounding benefits from weight loss, including improved energy, mobility, and overall quality of life.
Semaglutide Dosing for Insulin Resistance
Semaglutide is taken as a once-weekly subcutaneous injection. The standard titration starts at 0.25mg and gradually increases to the maintenance dose of 2.4mg over 16-20 weeks. Dosing is the same regardless of the indication — your provider will monitor your response and adjust timing as needed.
Cost of Semaglutide for Insulin Resistance
Compounded semaglutide costs $149-399/month through telehealth providers. Brand-name Wegovy costs $1,300+/month without insurance. Many patients with insulin resistance have associated comorbidities that improve insurance coverage chances.